Readoutin 104d
Madrigal Pharmaceuticals, Inc. — Resmetirom
Phase 3 primary completion: A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE).
- Date
- Mar 2027
- Type
- Readout
- Indication
- Non-Alcoholic Fatty Liver Disease